Literature DB >> 9286282

Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ.

Y Matsumoto1, D H Johnson.   

Abstract

PURPOSE: To determine the effect of dexamethasone on the phagocytic capacity of the human trabecular meshwork. A decrease in meshwork phagocytosis has been proposed in the pathogenesis of steroid glaucoma.
METHODS: The anterior segments of seven pairs of human eyes were placed in perfusion organ culture. One eye of each pair received dexamethasone, and the fellow eye served as control. After 21 days, latex microspheres labeled with fluorescein isothiocyanate and coated with antibodies were added to the culture medium. Twenty-four hours later, the eyes were fixed, the trabecular meshworks were treated with a rhodamine-labeled secondary antibody and sectioned, and the number of ingested beads was determined using a laser scanning confocal microscope. Nuclei were counted and used to calculate the phagocytic index of each anterior segment (number of ingested beads divided by number of nuclei).
RESULTS: Ingested beads appeared green and could be differentiated from noningested beads, which appeared red, using appropriate wavelengths of the laser. Bead ingestion was confirmed with electron microscopy and the use of secondary antibody labeled with horseradish peroxidase. Dexamethasone decreased phagocytosis by 57%, as shown by the fact that trabecular cells in dexamethasone-treated meshworks ingested significantly fewer beads than cells in fellow control meshworks (1.5 +/- 0.6 beads/cell versus 3.5 +/- 1.4 beads/cell; P = 0.008). No evidence of significant migration or loss of trabecular cells was noted; the number of trabecular cells appeared similar in dexamethasone-treated and control meshworks (144 +/- 36 versus 141 +/- 46).
CONCLUSIONS: Dexamethasone inhibits phagocytosis by human trabecular meshwork cells in perfusion organ culture.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286282

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  35 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma.

Authors:  Gary Hin-Fai Yam; Katarina Gaplovska-Kysela; Christian Zuber; Jürgen Roth
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 3.  The role of integrins in the trabecular meshwork.

Authors:  Debjani Gagen; Jennifer A Faralli; Mark S Filla; Donna M Peters
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-23       Impact factor: 2.671

Review 4.  Corticosteroids and glaucoma risk.

Authors:  R C Tripathi; S K Parapuram; B J Tripathi; Y Zhong; K V Chalam
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 5.  Role of the alternatively spliced glucocorticoid receptor isoform GRβ in steroid responsiveness and glaucoma.

Authors:  Ankur Jain; Robert J Wordinger; Thomas Yorio; Abbot F Clark
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-07       Impact factor: 2.671

6.  Cellular and cytoskeletal alterations of scleral fibroblasts in response to glucocorticoid steroids.

Authors:  Thania Bogarin; Sindhu Saraswathy; Goichi Akiyama; Xiaobin Xie; Robert N Weinreb; Jie Zheng; Alex S Huang
Journal:  Exp Eye Res       Date:  2019-08-23       Impact factor: 3.467

7.  Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus.

Authors:  Rosana Gerometta; Maria-Grazia Spiga; Teresa Borrás; Oscar A Candia
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

8.  RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis.

Authors:  Yalong Dang; Chao Wang; Priyal Shah; Susannah Waxman; Ralitsa T Loewen; Nils A Loewen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-11-19       Impact factor: 3.117

9.  Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model.

Authors:  Karen Y Torrejon; Ellen L Papke; Justin R Halman; Judith Stolwijk; Cula N Dautriche; Magnus Bergkvist; John Danias; Susan T Sharfstein; Yubing Xie
Journal:  Biotechnol Bioeng       Date:  2015-12-30       Impact factor: 4.530

Review 10.  Biological properties of trabecular meshwork cells.

Authors:  Joshua Z Gasiorowski; Paul Russell
Journal:  Exp Eye Res       Date:  2008-08-26       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.